Literature DB >> 8087402

A short form of the Mississippi Scale for measuring change in combat-related PTSD.

A Fontana1, R Rosenheck.   

Abstract

In large-scale surveys or program evaluations, investigators most often wish to assess multiple domains of functioning, while at the same time minimizing the overall length of the data collection protocols. In addition, studies of treatment interventions require instruments which offer the greatest opportunity of detecting change in the variables of interest. Toward these ends, we present an 11-item version of the Mississippi Scale for Combat-Related PTSD. The sample was composed of 436 war zone veterans who received specialized outpatient treatment for PTSD, and who were followed up in 4-month intervals for 1 year. Items were identified for inclusion in a short scale on half of the sample. The scale was then cross-validated on the other half. This short form of the Mississippi Scale has good internal consistency, good correspondence with the full scale, significant sensitivity to change in symptom severity, and significant relationships between change and clinicians' ratings of improvement after 1 year, number of treatment sessions received and number of months in treatment.

Entities:  

Mesh:

Year:  1994        PMID: 8087402     DOI: 10.1007/bf02102785

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  10 in total

1.  Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence.

Authors:  Ajay Manhapra; Elina Stefanovics; Robert Rosenheck
Journal:  Drug Alcohol Depend       Date:  2015-09-25       Impact factor: 4.492

2.  Treatment of female veterans with posttraumatic stress disorder: the role of comfort in a predominantly male environment.

Authors:  Alan Fontana; Robert Rosenheck
Journal:  Psychiatr Q       Date:  2006

3.  Correlates of Obtaining Employment among Veterans Receiving Treatment for Severe PTSD in Specialized Intensive Programs.

Authors:  Brian J Stevenson; Lisa Mueller; Megan M Kelly; Robert A Rosenheck
Journal:  Psychiatr Q       Date:  2021-01-06

4.  Correlates of improvement in substance abuse among dually diagnosed veterans with post-traumatic stress disorder in specialized intensive VA treatment.

Authors:  Kendell L Coker; Elina Stefanovics; Robert Rosenheck
Journal:  Psychol Trauma       Date:  2015-06-29

5.  Predictors of chronic trauma-related symptoms in a community sample of New Zealand motor vehicle accident survivors.

Authors:  Nikolaos Kazantzis; James Kennedy-Moffat; Ross A Flett; Alexandra M Petrik; Nigel R Long; Bronwyn Castell
Journal:  Cult Med Psychiatry       Date:  2012-09

6.  Residential Treatment for Posttraumatic Stress Disorder in the Department of Veterans Affairs: A National Perspective on.

Authors:  Joan M Cook; Stephanie Dinnen; Vanessa Simiola; Nancy Bernardy; Robert Rosenheck; Rani Hoff
Journal:  Traumatology (Tallahass Fla)       Date:  2014

7.  Continuity of care and clinical effectiveness: treatment of posttraumatic stress disorder in the Department of Veterans Affairs.

Authors:  Greg A Greenberg; Robert A Rosenheck; Alan Fontana
Journal:  J Behav Health Serv Res       Date:  2003 Apr-Jun       Impact factor: 1.505

8.  Resilience during war: Better unit cohesion and reductions in avoidant coping are associated with better mental health function after combat deployment.

Authors:  Lisa M McAndrew; Sarah Markowitz; Shou-En Lu; Ashley Borders; David Rothman; Karen S Quigley
Journal:  Psychol Trauma       Date:  2016-07-25

9.  Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder.

Authors:  Samuel T Wilkinson; Elina Stefanovics; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2015-09       Impact factor: 4.384

10.  A validation study of the Korean version of SPAN.

Authors:  Ho-Jun Seo; Sangkeun Chung; Hyun-Kook Lim; Ik-Seung Chee; Kyoung-Uk Lee; Ki-Chung Paik; Daeho Kim; Sang-Yeol Lee; Seung-Ho Ryu; Jung Bum Kim; Tae-Suk Kim; Won Kim; Jeong-Ho Chae
Journal:  Yonsei Med J       Date:  2011-07       Impact factor: 2.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.